1. What Is the Opioid Addiction Market?
The Opioid Addiction Market covers the medications for opioid use disorder that address the physical dependence, the craving, and the relapse prevention for the estimated 16 million people with the opioid use disorder globally. These people are at risk for the overdose death that claimed over 80,000 lives in the United States alone in 2022 from the synthetic opioid fentanyl and its analogues. OUD treatment uses the FDA-approved medications including the full agonist methadone that requires the daily supervised dispensing at the opioid treatment programme. The partial agonist buprenorphine can be provided by office-based prescribers with the patient takehome doses, and the extended-release naltrexone monthly injection serves the abstinence-based OUD patient. The OUD medication market is expanding with the DATA 2000 waiver elimination in the 2023 Omnibus appropriations bill that removed the requirement for the special DEA buprenorphine waiver training. The waiver training had limited the prescribers who could provide the office-based buprenorphine treatment. The elimination opened buprenorphine prescribing to all DEA-licensed Schedule III prescribers and dramatically expanded the accessible prescriber network.
2. Opioid Addiction Market Size & Forecast
3. Emerging Technologies
- DATA 2000 X-waiver elimination removing the buprenorphine prescribing special training requirement that the Drug Addiction Treatment Act of 2000 required for the office-based OUD treatment has dramatically expanded the prescriber pool. The medication for opioid use disorder MOUD treatment requires the buprenorphine that the expanded prescriber pool can now provide. The prescriber pool grew from the previously waivered 100,000 prescribers to the more than 1.1 million DEA-licensed practitioners who can now prescribe Schedule III controlled substances.
- Buprenorphine takehome dose supply concern arises from the diversion of the excess medication that the patient receives but does not use for self-administration. The illicit market absorbs the diverted medication for the unprescribed use. The monthly Sublocade depot injection eliminates the diversion for the patient who receives the single-dose injection that cannot be diverted to the secondary market that the daily sublingual tablet opportunity creates.
- Naloxone access expansion for the opioid overdose reversal uses the intranasal Narcan and the high-dose intranasal Kloxxado 8 mg formulation. The fentanyl-concentration increase requires the higher dose for the reversal that the standard 4 mg Narcan may not achieve. The high potency fentanyl and the naloxone-resistant carfentanil that the illicit supply includes drive the demand for the harm reduction tool.
- Low-barrier buprenorphine services at the pharmacy, the emergency department, and the primary care setting are enabled by the MATTER Act and the OTP expansion regulations. The services reach the patient who arrives at the healthcare system at the moment of the motivational readiness. The missed appointment and the treatment access barrier that the specialist referral created previously allowed the patient to lose the moment. The low-barrier prescribing captures the moment of readiness.
Similar technologies are also transforming adjacent markets. Learn more in our Alcohol USe Disorder Market.
4. Key Market Opportunity
Substantial growth potential in the Opioid Addiction market is over-the-counter naloxone access expansion, where the FDA approval of OTC Narcan and broader community naloxone distribution grow access for emergency overdose reversal in the ongoing opioid crisis. Companies with approved OTC naloxone capture this expanding public health distribution market. Additional momentum is centered on long-acting injectable buprenorphine adoption. As OTC naloxone distribution expands and LAI buprenorphine adoption grows, the addressable opportunity is expanding from prescription-only OUD treatment toward broader public health overdose reversal access and improved chronic OUD adherence.
5. Top Companies in the Opioid Addiction Market
The following organisations hold leading positions in the Opioid Addiction Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Indivior
- Alkermes
- Camurus
- Braeburn
- Titan Pharmaceuticals
- Mallinckrodt
- Orexo
- BioCorRx
- Sun Pharma
6. Market Segmentation
The Opioid Addiction Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug | BuprenorphineMethadoneNaltrexoneNaloxone |
| By Indication | MaintenanceDetoxificationOverdose Reversal |
| By Formulation | OralSublingualLong-Acting InjectableImplant |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Opioid Addiction Market trajectory over the forecast period:
DATA 2000 X-Waiver Elimination Removing Buprenorphine Prescribing Special Training Requirement Has Expanded the Prescriber Pool From 100,000 Waivered Practitioners to 1.1 Million DEA-Licensed Schedule III Prescribers Who Can Now Provide Office-Based OUD Treatment.Indivior's buprenorphine-naloxone sublingual film lost patent protection in 2020, and generic versions from Alvogen, Teva Pharmaceutical, and Dr. Reddy's now comprise over 95% of buprenorphine-naloxone prescriptions at list prices 70-80% below branded Suboxone. The shift to generic buprenorphine-naloxone has improved OUD treatment access in the US Medicaid population that accounts for over 40% of OUD treatment prescribing, with states reducing prior-authorisation requirements and maximising generic dispensing to stretch Medicaid addiction treatment budgets. Indivior's commercial strategy has shifted from branded Suboxone film to extended-release injectable Sublocade where no generic competition exists, focusing R&D investment on the premium adherence-optimised formulation segment of the OUD market rather than competing with its own generic successors.
Monthly Sublocade Depot Injection Eliminating Buprenorphine Diversion Risk and Daily Dose Decision Has Addressed the Two Primary Barriers to Sublingual Buprenorphine MOUD That Supervised Daily Dosing and High Diversion Potential Created for Community-Based OUD Treatment.The DEA's temporary waiver during COVID-19 enabling telephone and video initiation of buprenorphine without prior in-person evaluation has been extended indefinitely for practitioners completing 8-hour training, eliminating the geographic barrier that previously required rural OUD patients to travel hours for office visits. Telehealth OUD treatment platforms including Groups, Bicycle Health, and Workit Health are operating in over 40 states, providing same-day buprenorphine access from initial encounter to prescription for patients who contact the platform during a crisis period when treatment motivation is highest. Population-level data from states with telehealth OUD buprenorphine shows 25-35% increase in OUD treatment initiation rates following waiver implementation, suggesting that eliminating the in-person requirement increased the proportion of OUD patients who enter pharmacological treatment.
Low-Barrier Emergency Department and Primary Care Buprenorphine Initiation Capturing the Motivational Readiness Moment Without Specialist Referral Wait Has Established the Point-of-Care MOUD Model That the Opioid Overdose Crisis Urgency Requires for the At-Risk Patient Seeking Help.The Bernese method of buprenorphine microdosing starting at 0.2-0.5 mg per day and gradually increasing over 7-14 days while maintaining the patient's opioid use allows buprenorphine initiation without precipitated withdrawal from the high-affinity partial agonist displacing fentanyl in mu-opioid receptors, addressing a major clinical barrier in the fentanyl era where standard induction methods create severe precipitated withdrawal due to fentanyl's prolonged tissue sequestration. Fentanyl's 24-48-hour tissue half-life after chronic use makes conventional buprenorphine induction protocols requiring 12-24 hours of abstinence clinically dangerous, since residual fentanyl is displaced by buprenorphine even after apparent opioid washout. Widespread adoption of Bernese microdosing protocols in hospital ED and inpatient medicine settings is expanding buprenorphine initiation to fentanyl-dependent patients who previously could not tolerate standard induction, representing the most significant practical advance in OUD clinical management since extended-release injectable buprenorphine approval.
For related market intelligence, see the Addiction Treatment Market.
8. Segmental Analysis
By drug, the buprenorphine segment dominated the Opioid Addiction Market in 2025, as Indivior's Suboxone and its generics anchored office-based medication-assisted treatment across the large diagnosed population, generating the largest treatment volume in the indication across addiction care settings.
By formulation, the long-acting injectable segment is projected to register the highest growth rate through 2034, as Indivior's monthly Sublocade and Camurus's depot buprenorphine improve adherence and reduce misuse, addressing the central challenge of treatment retention in opioid use disorder.
9. Regional Analysis
Regional demand patterns across the Opioid Addiction Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Opioid Addiction Market in 2025, accounting for approximately 45% of global revenue, attributed to the US opioid crisis driving substantial OUD treatment demand and the broad office-based buprenorphine prescribing following X-waiver elimination. Moreover, OTC Narcan launch has expanded naloxone distribution. In addition, LAI Sublocade adoption is most advanced in the US. Regional dominance is due to this combination of crisis-driven demand and policy reform.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Opioid Addiction Market through 2034, driven by expanding OUD treatment access across European healthcare systems and the established harm reduction infrastructure including methadone and buprenorphine availability. The region is also witnessing LAI buprenorphine adoption growing. Moreover, naloxone harm reduction distribution is expanding. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Opioid Addiction Market was valued at USD 4.43 Bn in 2025 and is projected to reach USD 9.47 Bn by 2034, growing at a CAGR of 8.8% over the 2026–2034 forecast period.
The Opioid Addiction Market is projected to grow at a CAGR of 8.8% from 2026 to 2034.
North America dominated the Opioid Addiction Market in 2025, accounting for approximately 45% of global revenue, attributed to the US opioid crisis driving substantial OUD treatment demand and the broad office-based buprenorphine prescribing following X-waiver elimination.
The leading companies in the Opioid Addiction Market include Indivior, Alkermes, Camurus, Braeburn, Titan Pharmaceuticals, Mallinckrodt, Orexo, BioCorRx, Sun Pharma.
Data 2000 x-waiver elimination removing buprenorphine prescribing special training requirement has expanded the prescriber pool from 100,000 waivered practitioners to 1.1 million dea-licensed schedule iii prescribers who can now provide office-based oud treatment.
By drug, the buprenorphine segment dominated the Opioid Addiction Market in 2025, as Indivior's Suboxone and its generics anchored office-based medication-assisted treatment across the large diagnosed population, generating the largest treatment volume in the indication across addiction care settings.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.